Collectively, we showed that the suppression of the IL-22-STAT3-IGFBP5 axis is a key contributor to impaired endometrial receptivity in PCOS, providing a potential therapeutic target for improving pregnancy outcomes via IGFBP5 supplementation. This evidence concerns the gene IGFBP5 and polycystic ovary syndrome.